Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM15MRZ)

Drug Name

IMR-687 Drug Info

Synonyms

Tovinontrine; UNII-W248Y1AKOR; W248Y1AKOR; 2062661-53-2; a]pyrazin-8(7H)-one; CHEMBL4297290; SCHEMBL20358493; BDBM426313; US10513524, Compound (P3; 6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-; yl)methyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-; 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7himidazo(1,5-a)pyrazin-8-one; Imidazo(1,5-a)pyrazin-8(7H)-one, 6-((3S,4S)-4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl)-3-(tetrahydro-2H-pyran-4-yl)-

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 2	[1]

Cross-matching ID

PubChem CID: 124220601
CAS Number: CAS 2062661-53-2
TTD Drug ID: DM15MRZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phosphodiesterase 9 (PDE9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-4447943	DM81D4I	Alzheimer disease	8A20	Phase 2	[3]
ASP-4901	DMZUAH2	Genitourinary disease	GA0Z-GC8Z	Phase 2	[4]
E2027	DMK8SY6	Lewy body dementia	6D82	Phase 2	[5]
BI-409306	DMJFDS0	Alzheimer disease	8A20	Phase 2	[6]
CRD-740	DMRTX0K	Heart failure	BD10-BD13	Phase 2	[7]
TT-00920	DMP6G0P	Heart failure	BD10-BD13	Phase 1	[8]
SCH51866	DMCWSJP	Discovery agent	N.A.	Investigative	[9]
PF-4181366	DMC8G4S	Cognitive impairment	6D71	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 9 (PDE9)	TTZOEBC	PDE9A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03401112) A Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-beta0 Thalassemia). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Imara.
3	A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033070)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Clinical pipeline report, company report or official report of Boehringer Ingelheim pipeline.
7	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
8	Clinical pipeline report, company report or official report of TransThera Biosciences
9	Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998 Jun 19;273(25):15559-64.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1309).